Dong Z Y, Ward N E, Fan D, Gupta K P, O'Brian C A
Department of Cell Biology, University of Texas M. D. Anderson Cancer Center, Houston 77030.
Mol Pharmacol. 1991 Apr;39(4):563-9.
We investigated the effects that phorbol ester and diacylglycerol protein kinase C (PKC) activators had on the chemosensitivity of the human colon cancer cell line KM12L4a to Adriamycin (ADR), vincristine (VCR), and vinblastine (VLB) and on the intracellular accumulation of those drugs. Exposure of the cells to the PKC activator phorbol-12,13-dibutyrate (PDBu) (15 nM) during a 96-hr in vitro chemosensitivity assay significantly reduced the sensitivity of KM12L4a cells to ADR, VCR, and VLB, but not to 5-fluorouracil. Because a 96-hr treatment with 15 nM PDBu did not down-regulate PKC activity in KM12L4a cells, activation of PKC appeared to be responsible for the observed protection conferred by PDBu. PDBu-induced alterations in drug accumulation may account for its protective effects against these cytotoxic drugs, because both PDBu and the phorbol ester 12-O-tetradecanoyl-phorbol-13-acetate significantly reduced accumulation of [3H] VCR and [14C]ADR in the cultured human colon cancer cells. Unsaturated diacylglycerols are structural and functional analogues of phorbol ester PKC activators that are present in the lumen of the colon. We found that treatment of KM12L4a human colon cancer cells with the diacylglycerol 1-oleoyl-2-acetyl-sn-glycerol (OAG) significantly reduced [14C]ADR and [3H]VCR accumulation in the cells. The effects of OAG were dose dependent at physiological diacylglycerol concentrations and were completely reversed by the protein kinase inhibitor H7. OAG, which is rapidly metabolized in cultured cells, did not protect KM12L4a cells against the cytotoxic drugs in our 96-hr in vitro chemosensitivity assay. However, rapid metabolism of diacylglycerols should not limit their capacity to activate PKC in the colonic epithelium in vivo, because that tissue is chronically exposed to replenished supplies of unsaturated diacylglycerols in the intestinal tract. Our results provide evidence that unsaturated diacylglycerols may be environmental factors that contribute to the intrinsic drug resistance of colon cancer in vivo by reducing drug accumulation in the cancer cells.
我们研究了佛波酯和二酰基甘油蛋白激酶C(PKC)激活剂对人结肠癌细胞系KM12L4a对阿霉素(ADR)、长春新碱(VCR)和长春碱(VLB)的化学敏感性以及这些药物在细胞内蓄积的影响。在96小时的体外化学敏感性试验中,将细胞暴露于PKC激活剂佛波醇-12,13-二丁酸酯(PDBu)(15 nM)显著降低了KM12L4a细胞对ADR、VCR和VLB的敏感性,但对5-氟尿嘧啶无影响。由于用15 nM PDBu处理96小时并未下调KM12L4a细胞中的PKC活性,PKC的激活似乎是PDBu所赋予的观察到的保护作用的原因。PDBu诱导的药物蓄积改变可能解释了其对这些细胞毒性药物的保护作用,因为PDBu和佛波酯12-O-十四酰佛波醇-13-乙酸酯均显著降低了培养的人结肠癌细胞中[3H]VCR和[14C]ADR的蓄积。不饱和二酰基甘油是存在于结肠腔内的佛波酯PKC激活剂的结构和功能类似物。我们发现用二酰基甘油1-油酰基-2-乙酰基-sn-甘油(OAG)处理KM12L4a人结肠癌细胞显著降低了细胞中[14C]ADR和[3H]VCR的蓄积。在生理二酰基甘油浓度下,OAG的作用呈剂量依赖性,并且被蛋白激酶抑制剂H7完全逆转。OAG在培养细胞中迅速代谢,在我们96小时的体外化学敏感性试验中并未保护KM12L4a细胞免受细胞毒性药物的影响。然而,二酰基甘油的快速代谢不应限制其在体内结肠上皮中激活PKC的能力,因为该组织长期暴露于肠道中补充的不饱和二酰基甘油供应。我们的结果提供了证据,表明不饱和二酰基甘油可能是通过减少癌细胞中的药物蓄积而导致体内结肠癌固有耐药性的环境因素。